The number of confirmed cases of pneumonia in Wuhan in Hong Kong continued to rise, rising to 115 as of 10 days. The company`s new antiviral drug, Rhett Sivir (Remdesivir), has arrived in Hong Kong as soon as this week from Singapore, and three public hospitals in Hong Kong are conducting clinical trials, including Mary`s Hospital, Margaret`s Hospital and Prince of Wales Hospital, the United States pharmaceutical company Gillid Science (Gilead Sciences) announced.
The company`s new antiviral drug, Rhett Sivir (Remdesivir), has arrived in Hong Kong as soon as this week from Singapore and three public hospitals in Hong Kong are conducting clinical trials, the United States pharmaceutical company Geely De Science (Gilead Sciences) announced. (Image source: Pixabay)
According to the report, geelyde science announced late last month that it will launch a random distribution, open labels, a global intake of about 1000 patients, Wuhan pneumonia confirmed adults, a trial to assess the safety and efficacy of redcevir. The Hong Kong Pharmacy and Poisons Board issued a clinical trial certificate last week to conduct research in Hong Kong, Gillard Science said in a statement.
Professor Xu Shuchang, a professor of respiratory sciences at the Chinese University, said the study focused on patients in the Asian region, with 400 serious patients and 600 mild to moderate patients expected to participate. With regard to the number of patients participating in Hong Kong, the number of new cases after the arrival of the drug in Hong Kong is dependent on the number of new cases, which "will be used by those who are seriously ill and who are admitted to hospital ", so that the efficacy of the new drug can be assessed and the effectiveness of the other drugs used can be compared.
He said healthy people had also conducted a Rhettsivide clinical test, which found a slight increase in liver enzymes in some patients, but he didn`t think it was necessary to worry too much at this stage.
Among other asian countries involved in the reidceve clinical trial were TW 、 south korea, singapore and japan, but because the hong kong epidemic is temporarily stable, other countries are expected to be more patient than hong kong. Three hospitals in Hong Kong participated in clinical trials, including Mary Hospital, Margaret Hospital and Prince of Wales Hospital. The drug is said to be suitable for patients aged 18 or over, although it is not suitable for pregnant women or patients with renal failure.
